Axonal amyloid precursor protein and its fragments undergo somatodendritic endocytosis and processing
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index; 3 of the 30 sources its claims cite were checked for support.
Abstract
Deposition of potentially neurotoxic Aβ fragments derived from amyloid precursor protein (APP) at synapses may be a key contributor to Alzheimer's disease. However, the location(s) of proteolytic processing and subsequent secretion of APP fragments from highly compartmentalized, euploid neurons that express APP and processing enzymes at normal levels is not well understood. To probe the behavior of endogenous APP, particularly in human neurons, we developed a system using neurons differentiated from human embryonic stem cells, cultured in microfluidic devices, to enable direct biochemical measurements from axons. Using human or mouse neurons in these devices, we measured levels of Aβ, sAPPα, and sAPPβ secreted solely from axons. We found that a majority of the fragments secreted from axons were processed in the soma, and many were dependent on somatic endocytosis for axonal secretion. We also observed that APP and the β-site APP cleaving enzyme were, for the most part, not dependent on endocytosis for axonal entry. These data establish that axonal entry and secretion of APP and its proteolytic processing products traverse different pathways in the somatodendritic compartment before axonal entry.
Overview
CoChat Summary
TL;DR
In mouse and human neurons, axons secrete APP fragments, but most axonal Aβ is processed in the soma through secretase- and endocytosis-dependent pathways. Full-length APP and BACE can still enter axons via endocytosis-independent routes, indicating multiple sorting pathways.
Key findings
- Mouse hippocampal axons secreted Aβ40 at 17.1 ± 4.9 pM per chamber versus 588 ± 364 pM in bulk culture; estimated secretion was 4.0 × 10^5 ± 6 × 10^4 Aβ40 molecules per axon and 7.3 × 10^5 ± 2 × 10^5 per soma over 24 h, with axons contributing 37 ± 4% of total neuronal Aβ40.
- Human hESC-derived neurons secreted axonal Aβ40 at 45 ± 10 pM, Aβ42 at 10 ± 3 pM, sAPPβ at 58 ± 10 pM, and sAPPα at 210 ± 80 pM; per axon over 24 h, secretion was 1.7 × 10^6 ± 5.3 × 10^5 sAPPβ, 2.3 × 10^6 ± 6.6 × 10^5 sAPPα, 1.7 × 10^6 ± 3.0 × 10^5 Aβ40, and 2.6 × 10^5 ± 1.1 × 10^4 Aβ42 molecules.
- Somatic secretase inhibition reduced axonal Aβ: mouse γ-secretase inhibition reduced axonal Aβ40 to 30 ± 10% of vehicle, and human Compound E treatment reduced axonal Aβ40 to 68 ± 3%; the authors estimate 70–90% of mouse and 60–70% of human axonal Aβ was processed in the soma.
- Somatic dynasore reduced axonal Aβ40 to 61 ± 10% while axonal MCP1 was unchanged; full-length APP axonal delivery and dendrite-to-axon ratios were unchanged, and ~75% of axonal APP vesicles were positive for an endosomal marker, with 48 ± 1.6% colocalizing with BACE.
Methods
- Human neurons were differentiated from hESC lines HUES9/HSF6 on PA6 feeders with SMAD inhibitor/noggin and BDNF/GDNF/cAMP; primary mouse hippocampal neurons were cultured from P0–P1 C57/BL6 or APP mutant pups.
- Microfluidic chambers separated somal and axonal compartments; fluidic isolation was verified with 4-kDa FITC-dextran, and conditioned media were assayed by electrochemiluminescent immunoassay for Aβ40/42, sAPPβ, sAPPα, and MCP1.
- Pharmacological treatments included Compound E, OM99-2, β-secretase inhibitor IV, and dynasore; analyses used immunocytochemistry, live imaging, Matlab-based colocalization, ANOVA/Tukey, ANCOVA, and Mann-Whitney tests.
Limitations
- Stated: axonal Aβ and soluble APP measurements showed high variability, possibly from degradation or cleavage after secretion; human per-soma measurements were not possible due to neuronal aggregates and nonneuronal cells; direct axonal inhibitor treatment was not possible because media flow also inhibited the somal compartment; dynasore inhibition was incomplete after 24 h; some APP antibodies had specificity limitations.
- Stated/evident: the work is in compartmentalized in vitro cultures, not in vivo, and species or neuron-type differences may affect how much local axonal processing occurs.
- Evident from the text: estimates of processing location depend on inhibitor diffusion/dilution assumptions and normalization, and imaging/colocalization cannot fully exclude stabilized vesicle pools or nonspecific antibody binding.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
1 Valid · 1 Not valid · 15 Not checked · 86 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“there is considerable evidence that overexpression of APP can alter the sorting and trafficking of APP in neurons (Cataldo et al., 2003; Muresan and Muresan, 2007).”
§ Axonal amyloid precursor protein and its fragments undergo somatodendritic endocytosis and processing > INTRODUCTION
What the sources say
- Disputedcites Cataldo et al., 2003 matched to “App Gene Dosage Modulates Endosomal Abnormalities of Alzheimer's Disease in a Segmental Trisomy 16 Mouse Model of Down Syndrome” (2003) sourceExperimental — accuracy not yet measured
Our copy of Cataldo et al. (2003) directly tests APP overexpression in neurons and reports the opposite of the claim: in the Results section 'App gene dosage modulates early endosomal morphology in Ts65Dn mice' (p. 6788-6789), basal forebrain neurons from transgenic lines with two- to sevenfold overexpression of mutant human APP had normal-sized rab5-positive early endosomes and normal EEA1, rab4 and rabaptin5 labeling, and the Figure 4 legend (p. 6789) states that 'App dosage alone does not promote the endocytic response.' The Discussion reinforces this: 'Although increased App gene dosage is necessary for endosome pathology to develop in Ts65Dn mice, it is not sufficient, because overexpressing APP alone did not cause endosome pathology or atrophy of basal forebrain neurons,' and that APP's ability to alter endosome function requires other genes in the trisomic MMU16 region. The paper therefore does not support the assertion that APP overexpression alters APP sorting/trafficking in neurons; it shows the endocytic/trafficking compartment is unperturbed by overexpression alone and requires triplication plus other loci. (LLM, conf=0.68)
Checked by a reasoning model — may be wrong.
- Not checked yetcites Muresan and Muresan, 2007 matched to “The Amyloid-β Precursor Protein Is Phosphorylated via Distinct Pathways during Differentiation, Mitosis, Stress, and Degeneration” (2007) source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition to the early-onset familial mutations with a clear etiology, AD risk variants, such as those found in the SorLA or ApoE genes, are also connected to sorting of APP (Rogaeva et al., 2007; Marzolo and Bu, 2009).”
§ Axonal amyloid precursor protein and its fragments undergo somatodendritic endocytosis and processing > DISCUSSION
What the sources say
- Partly supportedcites Rogaeva et al., 2007 matched to “The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease” (2007) sourceExperimental — accuracy not yet measured
The SorLA half of the claim is squarely supported: the Abstract and RESULTS/DISCUSSION report that inherited variants in the SORL1 (SorLA) neuronal sorting receptor are associated with late-onset AD and that SORL1 'directs trafficking of APP into recycling pathways' and 'plays a key physiological role in the differential sorting of APP holoprotein' (Abstract; RESULTS, siRNA/retromer paragraph; DISCUSSION). The ApoE half is not: our copy mentions APOE only in the INTRODUCTION, where Aβ accumulation is said to be associated with disease-causing inherited variants in the APP, PS1, PS2 and APOE genes (citing references 5,6), with no demonstration or statement that ApoE risk variants act through sorting of APP. So the sorting mechanism attributed here to ApoE variants rests on other work (e.g. Marzolo and Bu, 2009), not on Rogaeva et al. 2007. (LLM, conf=0.78)
- Supportedcites Marzolo and Bu, 2009 matched to “Lipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer's disease” (2009) source
Section 3.4 of Marzolo & Bu (2009) states that sorLA 'acts as a sorting receptor' that 'regulates APP trafficking into discrete intracellular compartments' and that 'inherited variants in the SORL1 gene are associated with late-onset AD', directly linking a SorLA risk variant to APP sorting. The apoE side is carried by Section 3.5, where the disease-related isoform apoE4 depends on apoER2 co-expression to drive endocytosis of the X11/APP complex with BACE ('thus creating a link between the disease related isoform of apoE with it[!] receptor in the amyloidogenic pathway'), together with Section 4's statement that 'the genetic association of apoE ε4 allele with late-onset AD was established more than a decade ago'. The claim is hedged ('connected to sorting of APP'), matching the review's level of assertion; the only softening is that the review says the apoE ε4 molecular mechanisms 'are still unclear', and the apoE4/APP-endocytosis effect is reported from a primary study [96] rather than generated by the authors. (LLM, conf=0.82)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Axons from human neurons secreted detectable amounts of Aβ40, Aβ42, sAPPβ, and sAPPα.”
§ Axonal amyloid precursor protein and its fragments undergo somatodendritic endocytosis and processing > RESULTS > Axons of neurons expressing endogenous APP secrete sAPP and Aβ
plainn = 14- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus axonal secretion of Aβ40 was ∼4 times higher from human neurons than from mouse neurons, possibly due to neuronal type or species differences.”
§ Axonal amyloid precursor protein and its fragments undergo somatodendritic endocytosis and processing > RESULTS > Axons of neurons expressing endogenous APP secrete sAPP and Aβ
hedgedstates an associationn = 7- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we developed a method to differentiate neurons from human embryonic stem cells (hESCs). This protocol produces postmitotic neurons expressing endogenous amounts of human proteins.”
§ Axonal amyloid precursor protein and its fragments undergo somatodendritic endocytosis and processing > RESULTS > Human neurons differentiated from embryonic stem cells
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
57 more claims
Create a free account to see all 103 claims and to verify the 25 references still open.
- It may state two separate claims as one. 29
- Probably not a substantial claim. 17
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The Aβ aggregation usually starts in the presynaptic axon terminals, where APP is transported by vesicles and becomes enriched [33, 42, 53].”
From Abnormal accumulation of extracellular vesicles in hippocampal dystrophic axons and regulation by the primary cilia in Alzheimer's disease (2023) · cites this paper as [53]
Experimental — accuracy not yet measuredIn the citing paper
“~40% of neuronal Aβ production takes place in axons (Niederst et al., 2015; Das et al., 2016).”
From Axonal generation of amyloid-β from palmitoylated APP in mitochondria-associated endoplasmic reticulum membranes (2021) · cites this paper as Niederst et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Axonal amyloid precursor protein and its fragments undergo somatodendritic endocytosis and processing > RESULTS > Axons of neurons expressing endogenous APP secrete sAPP and Aβ
“bulk (soma) culture conditioned media contained 600 ± 100 pM Aβ40 and 100 ± 30 pM Aβ42 in 200 μl of media over 24 h (n = 14; Figure 2B).”
§ Axonal amyloid precursor protein and its fragments undergo somatodendritic endocytosis and processing > RESULTS > Axons of neurons expressing endogenous APP secrete sAPP and Aβ
“(B) Number of molecules of Aβ40 secreted per axon or cell body of mouse neurons in 24 h. (C) sAPPβ, sAPPα, and Aβ40 and Aβ42 measurements from human differentiated neurons after 24 h, in compartments 30–40 d.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Axonal amyloid precursor protein and its fragments undergo somatodendritic endocytosis and processing > RESULTS > Most APP fragments secreted from axons are processed in the cell soma
“In hippocampal cultures, we found that inhibition of soma β- or γ-secretase activity caused a significant decrease in secretion of Aβ40 from the axons compared with vehicle-treated controls (Figure 3A).”
§ Axonal amyloid precursor protein and its fragments undergo somatodendritic endocytosis and processing > RESULTS > Most APP fragments secreted from axons are processed in the cell soma
“with a trend toward reduction in axonal Aβ40 to 64 ± 30% (n.s.; n = 6; Figure 3A).”
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Nikolaev A, 2009, Nature, 457, 981, 10.1038/nature07767”
Cited work 10.1038/nature07767 · retracted 2023-12-18 · notice 10.1038/s41586-023-06943-3 · this paper published 2015-01-15
Citations
Cites
1 retracted
RETRACTED ARTICLE: APP binds DR6 to trigger axon pruning and neuron death via distinct caspases
Nikolaev, A., McLaughlin, T., O’Leary, D. D. M., & Tessier-Lavigne, M. (2009) · Nature · doi:10.1038/nature07767 · Cited by 992
RetractedHighly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling
Chambers, S. M., Fasano, C. A., Papapetrou, E. P., Tomishima, M., Sadelain, M., & Studer, L. (2009) · Nature Biotechnology · doi:10.1038/nbt.1529 · Cited by 3,620 · cited 1×
“The timeline and procedure is briefly outlined in Figure 1A and is a combination of previously published protocols (Chambers et al., 2009; Yuan et al., 2011).”
MethodDynasore, a Cell-Permeable Inhibitor of Dynamin
Macia, E., Ehrlich, M., Massol, R., Boucrot, E., Brunner, C., & Kirchhausen, T. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.04.002 · Cited by 1,958 · cited 1×
“To do this, we used the dynamin inhibitor dynasore (Macia et al., 2006).”
MethodDesign and validation of a tool for neurite tracing and analysis in fluorescence microscopy images
Meijering, E., Jacob, M., Sarria, J. ‐. F., Steiner, P., Hirling, H., & Unser, M. (2004) · Cytometry Part A · doi:10.1002/cyto.a.20022 · Cited by 1,608 · cited 2×
“For calculation of D:A ratio, Map2-positive or p-NFH–positive neurites were traced and measured using the NeuronJ plug-in for ImageJ (Meijering et al., 2004).”
MethodInduction of Midbrain Dopaminergic Neurons from ES Cells by Stromal Cell–Derived Inducing Activity
Kawasaki, H., Mizuseki, K., Nishikawa, S., Kaneko, S., Kuwana, Y., Nakanishi, S., Nishikawa, S.-I., & Sasai, Y. (2000) · Neuron · doi:10.1016/s0896-6273(00)00083-0 · Cited by 1,277
Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells
Israel, M. A., Yuan, S. H., Bardy, C., Reyna, S. M., Mu, Y., Herrera, C., Hefferan, M. P., Van Gorp, S., Nazor, K. L., Boscolo, F. S., et al. (2012) · Nature · doi:10.1038/nature10821 · Cited by 1,253 · cited 1×
“The efficiency and neurotransmitter type are described in previously published reports for this PA6based induction method (Buytaert-Hoefen et al., 2004; Israel et al., 2012).”
MethodSelf-citationAxonopathy and Transport Deficits Early in the Pathogenesis of Alzheimer’s Disease
Stokin, G. B., Lillo, C., Falzone, T. L., Brusch, R. G., Rockenstein, E., Mount, S. L., Raman, R., Davies, P., Masliah, E., Williams, D. S., et al. (2005) · Science · doi:10.1126/science.1105681 · Cited by 1,214 · cited 1×
“In fact, overexpression of APP can cause alterations in axonal transport dynamics and change the content of axonal APP vesicles (Torroja et al., 1999; Gunawardena and Goldstein, 2001; Stokin et al., 2005; Muresan et al., 2009).”
BackgroundSelf-citationThe neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease
Rogaeva, E., Meng, Y., Lee, J. H., Gu, Y., Kawarai, T., Zou, F., Katayama, T., Baldwin, C. T., Cheng, R., Hasegawa, H., et al. (2007) · Nature Genetics · doi:10.1038/ng1943 · Cited by 1,167
A microfluidic culture platform for CNS axonal injury, regeneration and transport
Taylor, A. M., Blurton-Jones, M., Rhee, S. W., Cribbs, D. H., Cotman, C. W., & Jeon, N. L. (2005) · Nature Methods · doi:10.1038/nmeth777 · Cited by 1,153 · cited 4×
“Devices were molded by soft lithography using Sylgard 182 (Ellsworth Adhesives, Germantown, WI) as previously described (Taylor et al., 2005).”
BackgroundMethodInfluentialTrafficking and Proteolytic Processing of APP
Haass, C., Kaether, C., Thinakaran, G., & Sisodia, S. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006270 · Cited by 1,075 · cited 1×
“Full-length APP undergoes multiple proteolytic processing events, typically an α- or β-site cleavage step followed by γ-site cleavage by secretase proteins (Haass et al., 2012).”
BackgroundThe Genetics of Alzheimer Disease: Back to the Future
Bertram, L., Lill, C. M., & Tanzi, R. E. (2010) · Neuron · doi:10.1016/j.neuron.2010.10.013 · Cited by 834 · cited 2×
“Alterations of expression or processing of amyloid precursor protein (APP) are pathogenic (Bertram et al., 2010) and may lead to the characteristic synapse loss and neuronal death, which are key features of Alzheimer’s disease (AD; Coleman and Yao, 2003; Wei et al., 2009).”
BackgroundEvidence that production and release of amyloid beta-protein involves the endocytic pathway
Koo, E. H., & Squazzo, S. L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32449-3 · Cited by 829
Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport.
Koo, E. H., Sisodia, S. S., Archer, D. R., Martin, L. J., Weidemann, A., Beyreuther, K., Fischer, P., Masters, C. L., & Price, D. L. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.4.1561 · Cited by 733 · cited 15×
“APP puncta were labeled with two N-terminal or C-terminal antibodies to elucidate any possible sorting discrepancies between FLAPP or N- and C-terminal fragments and to control for antibody ambiguity.”
BackgroundInfluentialAndersen, O. M., Reiche, J., Schmidt, V., Gotthardt, M., Spoelgen, R., Behlke, J., von Arnim, C. A. F., Breiderhoff, T., Jansen, P., Wu, X., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503689102 · Cited by 655 · cited 1×
“SorLA influences the sorting of APP from late endosomes into recycling endosomes (Andersen et al., 2005), suggesting that polymorphisms could change the subcellular sorting of APP and have subsequent downstream localization effects.”
BackgroundEndocytosis Is Required for Synaptic Activity-Dependent Release of Amyloid-β In Vivo
Cirrito, J. R., Kang, J.-E., Lee, J., Stewart, F. R., Verges, D. K., Silverio, L. M., Bu, G., Mennerick, S., & Holtzman, D. M. (2008) · Neuron · doi:10.1016/j.neuron.2008.02.003 · Cited by 635 · cited 5×
“Previous work measuring Aβ in brain slices or cultures with established synapses indicates a majority of Aβ is released through synaptic vesicle exocytosis and is therefore most likely secreted solely from axon terminals (Cirrito et al., 2008; Tampellini et al., 2009).”
BackgroundResultInfluentialKamal, A., Almenar-Queralt, A., LeBlanc, J. F., Roberts, E. A., & Goldstein, L. S. B. (2001) · Nature · doi:10.1038/414643a · Cited by 583
Self-citationA Prospective Study of Alzheimer Disease in Down Syndrome
Lai, F., & Williams, R. S. (1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520440031017 · Cited by 561 · cited 2×
“Volume 26 January 15, 2015 205”
BackgroundKamal, A., Stokin, G. B., Yang, Z., Xia, C.-H., & Goldstein, L. S. B. (2000) · Neuron · doi:10.1016/s0896-6273(00)00124-0 · Cited by 544 · cited 2×
“By using this system, we discovered in mouse and human axons that production, 2) distal axons as one possible source of amyloid deposits, and 3) a link between axonal transport function and disease (Kamal et al., 2000; Lazarov et al., 2002; Abramov et al., 2009; Das et al., 2013).”
MethodSelf-citationAmyloid-β as a positive endogenous regulator of release probability at hippocampal synapses
Abramov, E., Dolev, I., Fogel, H., Ciccotosto, G. D., Ruff, E., & Slutsky, I. (2009) · Nature Neuroscience · doi:10.1038/nn.2433 · Cited by 499
Gunawardena, S., & Goldstein, L. S. B. (2001) · Neuron · doi:10.1016/s0896-6273(01)00496-2 · Cited by 428 · cited 1×
“In fact, overexpression of APP can cause alterations in axonal transport dynamics and change the content of axonal APP vesicles (Torroja et al., 1999; Gunawardena and Goldstein, 2001; Stokin et al., 2005; Muresan et al., 2009).”
BackgroundSelf-citationSleegers, K., Brouwers, N., Gijselinck, I., Theuns, J., Goossens, D., Wauters, J., Del-Favero, J., Cruts, M., Duijn, C. M. V., & Broeckhoven, C. V. (2006) · Brain · doi:10.1093/brain/awl203 · Cited by 407 · cited 1×
“Furthermore, a single extra copy of APP in the human genome will cause early-onset AD (Lai and Williams, 1989; Sleegers et al., 2006).”
BackgroundYuan, S. H., Martin, J., Elia, J., Flippin, J., Paramban, R. I., Hefferan, M. P., Vidal, J. G., Mu, Y., Killian, R. L., Israel, M. A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017540 · Cited by 380 · cited 2×
“For imaging experiments, differentiated neurons were fluorescence-activated cell sorted for neurons, as described previously (Yuan et al., 2011), and grown in glial-conditioned media.”
MethodSelf-citationZhao, J., Fu, Y., Yasvoina, M., Shao, P., Hitt, B., O'Connor, T., Logan, S., Maus, E., Citron, M., Berry, R., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4396-06.2007 · Cited by 365 · cited 3×
“…(Sigma-Aldrich, St. Louis, MO); N-terminal APP 5a3/1g7 (1:100) courtesy of Eddie Koo (Koo et al., 1996); BACE 3D5 (1:200) courtesy of Robert Vassar (Zhao et al., 2007); C-terminal APP Jonas clone (1:100), C-terminal APP AB5352 (1:100), NeuN (1:100), and Synaptophysin (1:100) (Chemicon/Millipore,…”
BackgroundAmyloid beta from axons and dendrites reduces local spine number and plasticity
Wei, W., Nguyen, L. N., Kessels, H. W., Hagiwara, H., Sisodia, S., & Malinow, R. (2010) · Nature Neuroscience · doi:10.1038/nn.2476 · Cited by 357 · cited 2×
“Alterations of expression or processing of amyloid precursor protein (APP) are pathogenic (Bertram et al., 2010) and may lead to the characteristic synapse loss and neuronal death, which are key features of Alzheimer’s disease (AD; Coleman and Yao, 2003; Wei et al., 2009).”
BackgroundSynaptic slaughter in Alzheimer's disease
Coleman, P. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.09.001 · Cited by 351 · cited 2×
“Alterations of expression or processing of amyloid precursor protein (APP) are pathogenic (Bertram et al., 2010) and may lead to the characteristic synapse loss and neuronal death, which are key features of Alzheimer’s disease (AD; Coleman and Yao, 2003; Wei et al., 2009).”
BackgroundNeurochemical diagnosis of Alzheimer’s dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau
Lewczuk, P., Esselmann, H., Otto, M., Maler, J. M., Henkel, A. W., Henkel, M. K., Eikenberg, O., Antz, C., Krause, W.-R., Reulbach, U., et al. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00086-1 · Cited by 308
Apical trafficking in epithelial cells: signals, clusters and motors
Weisz, O. A., & Rodriguez-Boulan, E. (2009) · Journal of Cell Science · doi:10.1242/jcs.032615 · Cited by 304 · cited 1×
“Volume 26 January 15, 2015 Neuronal somatodendritic APP processing | 211 This hybrid secretory/endocytic route has been observed in polarized epithelia for cargo such as p75 and apical-variant VSVG (Weisz and Rodriguez-Boulan, 2009).”
BackgroundLazarov, O., Lee, M., Peterson, D. A., & Sisodia, S. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-22-09785.2002 · Cited by 302 · cited 2×
“By using this system, we discovered in mouse and human axons that production, 2) distal axons as one possible source of amyloid deposits, and 3) a link between axonal transport function and disease (Kamal et al., 2000; Lazarov et al., 2002; Abramov et al., 2009; Das et al., 2013).”
MethodPresenilin-1 and -2 Are Molecular Targets for γ-Secretase Inhibitors
Seiffert, D., Bradley, J. D., Rominger, C. M., Rominger, D. H., Yang, F., Meredith, J. E., Wang, Q., Roach, A. H., Thompson, L. A., Spitz, S. M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005430200 · Cited by 301 · cited 2×
“8 pM for Compound E, 4 pM for OM99-2, and 8 pM for β inhibitor IV, which is well below the inhibitory constants of the inhibitors (IC50 = 100 nM Compound E, IC50 = 70 nM OM99-2, IC50 = 36 nM β inhibitor IV; Seiffert et al., 2000; Stachel et al., 2004; Garino et al., 2006).”
BackgroundInfluentialSannerud, R., Declerck, I., Peric, A., Raemaekers, T., Menendez, G., Zhou, L., Veerle, B., Coen, K., Munck, S., De Strooper, B., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100745108 · Cited by 286 · cited 3×
“In addition, APP and the secretase β-site APP-cleaving enzyme (BACE), which mediates amyloidogenic β-site cleavage events, are internalized through endocytosis via different endocytic pathways (Schneider et al., 2008; Sannerud et al., 2011; Morel et al., 2013).”
BackgroundMethodKinoshita, A., Fukumoto, H., Shah, T., Whelan, C. M., Irizarry, M. C., & Hyman, B. T. (2003) · Journal of Cell Science · doi:10.1242/jcs.00643 · Cited by 284 · cited 2×
“The reduction of axonal C-terminal APP vesicles by only 10 ± 3% indicates that most Volume 26 January 15, 2015 Neuronal somatodendritic APP processing | 213 Our studies of neurons using microfluidic chambers enabled us to directly measure the amounts of endogenous levels of secreted APP fragments…”
BackgroundDas, U., Scott, D. A., Ganguly, A., Koo, E. H., Tang, Y., & Roy, S. (2013) · Neuron · doi:10.1016/j.neuron.2013.05.035 · Cited by 282 · cited 8×
“In contrast, full-length unprocessed APP and BACE appeared to be sorted into axons through at least two pathways, one dependent on endocytosis, one not.”
BackgroundMethodInfluentialStachel, S. J., Coburn, C. A., Steele, T. G., Jones, K. G., Loutzenhiser, E. F., Gregro, A. R., Rajapakse, H. A., Lai, M.-T., Crouthamel, M.-C., Xu, M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049379g · Cited by 262 · cited 2×
“8 pM for Compound E, 4 pM for OM99-2, and 8 pM for β inhibitor IV, which is well below the inhibitory constants of the inhibitors (IC50 = 100 nM Compound E, IC50 = 70 nM OM99-2, IC50 = 36 nM β inhibitor IV; Seiffert et al., 2000; Stachel et al., 2004; Garino et al., 2006).”
BackgroundInfluentialCataldo, A. M., Petanceska, S., Peterhoff, C. M., Terio, N. B., Epstein, C. J., Villar, A., Carlson, E. J., Staufenbiel, M., & Nixon, R. A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-17-06788.2003 · Cited by 241 · cited 1×
“This is because there is considerable evidence that overexpression of APP can alter the sorting and trafficking of APP in neurons (Cataldo et al., 2003; Muresan and Muresan, 2007).”
BackgroundMorel, E., Chamoun, Z., Lasiecka, Z. M., Chan, R. B., Williamson, R. L., Vetanovetz, C., Dall’Armi, C., Simoes, S., Point Du Jour, K. S., McCabe, B. D., et al. (2013) · Nature Communications · doi:10.1038/ncomms3250 · Cited by 222 · cited 1×
“In addition, APP and the secretase β-site APP-cleaving enzyme (BACE), which mediates amyloidogenic β-site cleavage events, are internalized through endocytosis via different endocytic pathways (Schneider et al., 2008; Sannerud et al., 2011; Morel et al., 2013).”
BackgroundTraumatic brain injury and Alzheimer's disease: a review
Van Den Heuvel, C., Thornton, E., & Vink, R. (2007) · Progress in Brain Research · doi:10.1016/s0079-6123(06)61021-2 · Cited by 213 · cited 2×
“214 | E. D. Niederst et al. Molecular Biology of the Cell contributing to disease (Van Den Heuvel et al., 2007), which could be attributed to a neuronal stress response involving the location of processing or secretion.”
BackgroundMethodSchneider, A., Rajendran, L., Honsho, M., Gralle, M., Donnert, G., Wouters, F., Hell, S. W., & Simons, M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5345-07.2008 · Cited by 210 · cited 1×
“In addition, APP and the secretase β-site APP-cleaving enzyme (BACE), which mediates amyloidogenic β-site cleavage events, are internalized through endocytosis via different endocytic pathways (Schneider et al., 2008; Sannerud et al., 2011; Morel et al., 2013).”
BackgroundYamazaki, T., Selkoe, D. J., & Koo, E. H. (1995) · The Journal of cell biology · doi:10.1083/jcb.129.2.431 · Cited by 208 · cited 1×
“Sorting of APP and its proteolytic fragments in bona fide neurons is less understood, with evidence for multiple pathways, including dendritic to axon sorting and axon transport preceding dendritic sorting (Simons et al., 1995; Yamazaki et al., 1995; Koo et al., 1996).”
BackgroundTorroja, L., Chu, H., Kotovsky, I., & White, K. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80215-2 · Cited by 203 · cited 1×
“In fact, overexpression of APP can cause alterations in axonal transport dynamics and change the content of axonal APP vesicles (Torroja et al., 1999; Gunawardena and Goldstein, 2001; Stokin et al., 2005; Muresan et al., 2009).”
BackgroundKoo, E. H., Squazzo, S. L., Selkoe, D. J., & Koo, C. H. (1996) · Journal of Cell Science · doi:10.1242/jcs.109.5.991 · Cited by 201
Leterrier, C., Lainé, J., Darmon, M., Boudin, H., Rossier, J., & Lenkei, Z. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5437-05.2006 · Cited by 201 · cited 2×
“By using this system, we discovered in mouse and human axons that production, 2) distal axons as one possible source of amyloid deposits, and 3) a link between axonal transport function and disease (Kamal et al., 2000; Lazarov et al., 2002; Abramov et al., 2009; Das et al., 2013).”
BackgroundMethodAxonal Targeting of Trk Receptors via Transcytosis Regulates Sensitivity to Neurotrophin Responses
Ascaño, M., Richmond, A., Borden, P., & Kuruvilla, R. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1542-09.2009 · Cited by 178 · cited 2×
“By using this system, we discovered in mouse and human axons that production, 2) distal axons as one possible source of amyloid deposits, and 3) a link between axonal transport function and disease (Kamal et al., 2000; Lazarov et al., 2002; Abramov et al., 2009; Das et al., 2013).”
BackgroundMethodUncovering multiple axonal targeting pathways in hippocampal neurons
Wisco, D., Anderson, E. D., Chang, M. C., Norden, C., Boiko, T., Fölsch, H., & Winckler, B. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200307069 · Cited by 163 · cited 2×
“By using this system, we discovered in mouse and human axons that production, 2) distal axons as one possible source of amyloid deposits, and 3) a link between axonal transport function and disease (Kamal et al., 2000; Lazarov et al., 2002; Abramov et al., 2009; Das et al., 2013).”
BackgroundMethodKaether, C., Schmitt, S., Willem, M., & Haass, C. (2006) · Traffic · doi:10.1111/j.1600-0854.2006.00396.x · Cited by 149 · cited 1×
“The sorting of APP into the axon despite endocytic inhibition is consistent with work in nonneuronal cells that found that C99–green fluorescent protein was sorted normally when dynamin is blocked (Kaether et al., 2006).”
ResultBuytaert‐Hoefen, K. A., Alvarez, E., & Freed, C. R. (2004) · STEM CELLS · doi:10.1634/stemcells.22-5-669 · Cited by 147 · cited 1×
“The efficiency and neurotransmitter type are described in previously published reports for this PA6based induction method (Buytaert-Hoefen et al., 2004; Israel et al., 2012).”
MethodTampellini, D., Rahman, N., Gallo, E. F., Huang, Z., Dumont, M., Capetillo-Zarate, E., Ma, T., Zheng, R., Lu, B., Nanus, D. M., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2292-09.2009 · Cited by 127 · cited 3×
“This model is supported by evidence for colocalization of processing enzymes together with APP in vesicles (Kamal et al., 2001) and evidence that synaptic activity in vivo increases endocytosis-dependent Aβ release into the brain (Cirrito et al., 2008; Tampellini et al., 2009; Das et al., 2013).”
BackgroundMarzolo, M.-P., & Bu, G. (2009) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2008.10.005 · Cited by 122
Cai, D., Leem, J. Y., Greenfield, J. P., Wang, P., Kim, B. S., Wang, R., Lopes, K. O., Kim, S.-H., Zheng, H., Greengard, P., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209065200 · Cited by 118 · cited 18×
“214 | E. D. Niederst et al. Molecular Biology of the Cell contributing to disease (Van Den Heuvel et al., 2007), which could be attributed to a neuronal stress response involving the location of processing or secretion.”
BackgroundInfluentialThe somatodendritic endosomal regulator NEEP21 facilitates axonal targeting of L1/NgCAM
Yap, C. C., Wisco, D., Kujala, P., Lasiecka, Z. M., Cannon, J. T., Chang, M. C., Hirling, H., Klumperman, J., & Winckler, B. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200707143 · Cited by 114 · cited 1×
“For proteins previously demonstrated to travel to axons via transcytosis, inhibition of endocytosis greatly reduced the appearance of the protein in axons and increased in dendrites (represented by an increase in D:A ratio; Yap et al., 2008).”
BackgroundCarey, R. M., Balcz, B. A., Lopez-Coviella, I., & Slack, B. E. (2005) · BMC Cell Biology · doi:10.1186/1471-2121-6-30 · Cited by 112
Axonal Stress Kinase Activation and Tau Misbehavior Induced by Kinesin-1 Transport Defects
Falzone, T. L., Stokin, G. B., Lillo, C., Rodrigues, E. M., Westerman, E. L., Williams, D. S., & Goldstein, L. S. B. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0780-09.2009 · Cited by 101 · cited 2×
“Hippocampal neurons were dissected from P0-P1 C57/BL6 or APP+/− or APP−/− (Apptm1Dbo/J) pups as previously described (Falzone et al., 2009).”
MethodSelf-citationAmyloid Precursor Protein Revisited
Guo, Q., Li, H., Gaddam, S. S. K., Justice, N. J., Robertson, C. S., & Zheng, H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.315051 · Cited by 94
Simons, M., Ikonen, E., Tienari, P. J., Cid‐Arregui, A., Mönning, U., Beyreuther, K., & Dotti, C. G. (1995) · Journal of Neuroscience Research · doi:10.1002/jnr.490410114 · Cited by 94 · cited 2×
“Previous literature has been contradictory regarding the pathway utilized by APP for delivery to axons (Koo et al., 1990; Simons et al., 1995; Cai et al., 2003).”
BackgroundAxonal transport of APP and the spatial regulation of APP cleavage and function in neuronal cells
Brunholz, S., Sisodia, S., Lorenzo, A., Deyts, C., Kins, S., & Morfini, G. (2012) · Experimental Brain Research · doi:10.1007/s00221-011-2870-1 · Cited by 92 · cited 1×
“Fluidic separation of axons from neuronal cell bodies Region-specific aggregation of Aβ and synaptic toxicity of APP fragments raised the possibility that the regional processing and secretion of APP within a neuron may be an important factor in the pathogenesis of AD (Brunholz et al., 2012).”
BackgroundAxonal targeting of Caspr2 in hippocampal neurons via selective somatodendritic endocytosis
Bel, C., Oguievetskaia, K., Pitaval, C., Goutebroze, L., & Faivre-Sarrailh, C. (2009) · Journal of Cell Science · doi:10.1242/jcs.050526 · Cited by 74 · cited 1×
“Bel et al., 2009).”
Muresan, V., Varvel, N. H., Lamb, B. T., & Muresan, Z. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2558-08.2009 · Cited by 59 · cited 4×
“One model postulates that most APP is processed in the cell body and APP cleavage products are sorted into independent vesicles before entering the axon (Muresan et al., 2009).”
BackgroundMethodResultInfluentialGarino, C., Tomita, T., Pietrancosta, N., Laras, Y., Rosas, R., Herbette, G., Maigret, B., Quéléver, G., Iwatsubo, T., & Kraus, J.-L. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0602864 · Cited by 55 · cited 2×
“8 pM for Compound E, 4 pM for OM99-2, and 8 pM for β inhibitor IV, which is well below the inhibitory constants of the inhibitors (IC50 = 100 nM Compound E, IC50 = 70 nM OM99-2, IC50 = 36 nM β inhibitor IV; Seiffert et al., 2000; Stachel et al., 2004; Garino et al., 2006).”
BackgroundInfluentialMicrofluidic techniques : reviews and protocols
Minteer, S. D. (2006) · Cited by 52
Muresan, Z., & Muresan, V. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-07-0625 · Cited by 45 · cited 1×
“This is because there is considerable evidence that overexpression of APP can alter the sorting and trafficking of APP in neurons (Cataldo et al., 2003; Muresan and Muresan, 2007).”
BackgroundSzpankowski, L., Encalada, S. E., & Goldstein, L. S. B. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120510109 · Cited by 35 · cited 2×
“Individual slices (without deconvolution) were processed for colocalization in Matlab using a package developed in our lab, described and extensively validated previously using a 300-nm cutoff for colocalization (Szpankowski et al., 2012).”
MethodSelf-citationPark, J. W., Kim, H. J., Byun, J. H., Ryu, H. R., & Jeon, N. L. (2009) · Biotechnology Journal · doi:10.1002/biot.200900159 · Cited by 33 · cited 1×
“…better understand endogenous APP processing, localization, secretion, and sorting of APP and its fragments in neurons, we took advantage of compartmentalized culture systems that enable biochemical analyses by separating axons from bulk neuronal cultures (Taylor et al., 2005; Park et al., 2009).”
Background
Cited by
Myelin dysfunction drives amyloid-β deposition in models of Alzheimer’s disease
Depp, C., Sun, T., Sasmita, A. O., Spieth, L., Berghoff, S. A., Nazarenko, T., Overhoff, K., Steixner-Kumar, A. A., Subramanian, S., Arinrad, S., et al. (2023) · Nature · doi:10.1038/s41586-023-06120-6 · Cited by 493
Amyloid-β and tau complexity — towards improved biomarkers and targeted therapies
Polanco, J. C., Li, C., Bodea, L.-G., Martinez-Marmol, R., Meunier, F. A., & Götz, J. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.162 · Cited by 378
Cellular Functions of the Amyloid Precursor Protein from Development to Dementia
van der Kant, R., & Goldstein, L. S. B. (2015) · Developmental Cell · doi:10.1016/j.devcel.2015.01.022 · Cited by 245
Self-citationLópez-Erauskin, J., Tadokoro, T., Baughn, M. W., Myers, B., McAlonis-Downes, M., Chillon-Marinas, C., Asiaban, J. N., Artates, J., Bui, A. T., Vetto, A. P., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.09.044 · Cited by 233
The Endolysosomal System and Proteostasis: From Development to Degeneration
Winckler, B., Faundez, V., Maday, S., Cai, Q., Guimas Almeida, C., & Zhang, H. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.1665-18.2018 · Cited by 107
“…Hernandez et al., 2012; Shehata et al., 2012; Binotti et al., 2015; Lüningschrör et al., 2017; Nikoletopoulou et al., 2017; Ok- erlund et al., 2017; Nikoletopoulou and Tavernarakis, 2018), mitochondria (Cai et al., 2012; Maday et al., 2012; Ashrafi et al., 2014; Rangaraju et al., 2014; Wong…”
Background
Metadata
- Authors
- Niederst, E. D., Reyna, S. M., & Goldstein, L. S. B.
- Affiliations
- University of California San Diego (US)
- Boston Children's Hospital (US)
- Corresponding author
- Goldstein, Lawrence S. B.
- Venue
- Molecular Biology of the Cell
- Published
- 2015-01-15
- Volume
- 26
- Issue
- 2
- Pages
- 205-217
- ISSN
- 1059-1524 (ISSN-L)
- 1939-4586
- PMC
- PMC4294669
- OpenAlex
- W2321039262
- Cited by
- 51
- References
- 61
- Citations by year
- 2025: 4 · 2024: 3 · 2023: 5 · 2022: 8 · 2021: 5 · 2020: 5 · 2019: 4 · 2018: 8 · 2017: 2 · 2016: 4 · 2015: 3
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- cc-by-nc-sa
- Locations
- Molecular Biology of the Cell (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute on Aging (P50AG005131)
- National Institute of General Medical Sciences (T32GM008666)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- amyloid precursor protein, axons, APP processing, amyloid-beta, sAPPα, sAPPβ, human embryonic stem cell-derived neurons, microfluidics, Alzheimer's disease, synapses
- MeSH terms
- Animals, Axons, Benzodiazepinones, Cell Differentiation, Cell Line, Cells, Cultured, Dendrites, Endocytosis, Humans, Hydrazones, Luminescent Proteins, Mice, Inbred C57BL, Oligopeptides, Peptide Fragments, Signal Transduction, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Mice, Knockout, Microscopy, Confocal, Microfluidic Analytical Techniques, Embryonic Stem Cells, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-19, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-19 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.